Last reviewed · How we verify
Imferon (IRON DEXTRAN)
Imferon works by providing the body with iron, a crucial component for the production of hemoglobin, which carries oxygen in the blood.
Imferon, also known as Iron Dextran, is a medication used to treat iron deficiency anemia. It is a complex of iron and dextran, a type of sugar molecule. Imferon is administered intramuscularly or intravenously and is available in the United States as a brand-name product due to its off-patent status. The medication is not well-characterized in terms of its pharmacokinetic properties, and its exact mechanism of action is not fully understood. As a result, it is primarily used as a treatment for iron deficiency anemia in patients who are unable to take oral iron supplements.
At a glance
| Generic name | IRON DEXTRAN |
|---|---|
| Sponsor | Allergan |
| Therapeutic area | Hematology |
| Phase | discontinued |
Mechanism of action
The circulating iron released from iron dextran, which is subject to physiological control, replenishes hemoglobin and depleted iron stores.
Approved indications
Common side effects
- Anaphylactic reactions
- Cardiovascular collapse
- Respiratory difficulty
- Cardiac arrest
- Shock
- Hypertension
- Hypotension
- Tachycardia
- Bradycardia
- Flushing
- Arrhythmias
- Urticaria
Key clinical trials
- Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma (PHASE2)
- Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.
- Establishment of a Microfluidic Based Liquid Biopsy Platform for Recurrent/Metastatic Head and Neck Cancers Prognostication Using NK Cell IFN-γ Expression and CTM Correlation With DS-SACA Chip
- A Phase 1 Study of PVT401 in Healthy Subjects (PHASE1)
- The Role of Ferric Carboxymaltose in the Treatment of Pediatric Iron Deficiency Anemia in the Emergency Department (PHASE4)
- Study of EL219 vs Standard of Care for Early Antifungal Therapy of Suspected Invasive Mould Infections (PHASE2)
- Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants (PHASE2)
- Daily Iron vs Every-other-day Iron for Pediatric Patients With IDA (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Imferon CI brief — competitive landscape report
- Imferon updates RSS · CI watch RSS